Glesatinib hydrochloride
| CAS No. | 1123838-51-6 | Cat. No. | BCP18872 |
| Name | Glesatinib hydrochloride | ||
| Synonyms | MGCD265 hydrochloride;MGCD 265 hydrochloride;MGCD-265 hydrochloride; | ||
| Formula | C31H27ClF2N5O3S2X | M. Wt | 655.16 |
| Description | Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. Glesatinib, also known as MGCD-265, is an orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. MGCD265 binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | TAM Receptor c Met Tie2 | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.